Literature DB >> 16000959

A novel flow cytometric assay for evaluating cell-mediated cytotoxicity.

Mark W Burkett1, Kimberly A Shafer-Weaver, Susan Strobl, Michael Baseler, Anatoli Malyguine.   

Abstract

Comprehensive evaluation of cell-mediated cytotoxicity is very important, especially in the clinical setting, when a surrogate immunologic endpoint that correlates with a clinical outcome needs to be defined. With the objective of simultaneously evaluating target cell death and effector cell frequency, the authors combined the measuring of the expression of the degranulation marker CD107a by effector cells with the apoptosis marker annexin V binding to target cells. Using human cytotoxic T lymphocytes, the authors found a significant incubation time-dependent increase of surface CD107a expression on effector cells due to degranulation. A parallel increase of annexin V binding to target cells due to target cell apoptosis was also found. These two parameters have shown excellent correlation in all effector/target cell systems studied. To find possible connections between effector cell degranulation (CD107a expression), granzyme B secretion, and target cell death (annexin V binding), the GrB ELISPOT assay and flow cytometric assay were performed and excellent cross-correlation was found between all three parameters. The specificity of the assay was also shown. These data show that this novel assay allows measurement of cytolytic cell activation and frequency as well as target cell death in the same sample.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16000959     DOI: 10.1097/01.cji.0000165357.11548.6d

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  17 in total

Review 1.  New flow cytometric assays for monitoring cell-mediated cytotoxicity.

Authors:  Liubov Zaritskaya; Michael R Shurin; Thomas J Sayers; Anatoli M Malyguine
Journal:  Expert Rev Vaccines       Date:  2010-06       Impact factor: 5.217

2.  Gamma interferon secretion by human Vgamma2Vdelta2 T cells after stimulation with antibody against the T-cell receptor plus the Toll-Like receptor 2 agonist Pam3Cys.

Authors:  Carl O Deetz; Andrew M Hebbeler; Nadia A Propp; Cristiana Cairo; Illia Tikhonov; C David Pauza
Journal:  Infect Immun       Date:  2006-08       Impact factor: 3.441

Review 3.  Pushing the frontiers of T-cell vaccines: accurate measurement of human T-cell responses.

Authors:  Fadi Saade; Stacey Ann Gorski; Nikolai Petrovsky
Journal:  Expert Rev Vaccines       Date:  2012-12       Impact factor: 5.217

4.  Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines.

Authors:  Cory L Ahonen; Anna Wasiuk; Shinichiro Fuse; Mary Jo Turk; Marc S Ernstoff; Arief A Suriawinata; James D Gorham; Ross M Kedl; Edward J Usherwood; Randolph J Noelle
Journal:  Blood       Date:  2008-01-17       Impact factor: 22.113

5.  T cells targeting NY-ESO-1 demonstrate efficacy against disseminated neuroblastoma.

Authors:  Nathan Singh; Irina Kulikovskaya; David M Barrett; Gwendolyn Binder-Scholl; Bent Jakobsen; Daniel Martinez; Bruce Pawel; Carl H June; Michael D Kalos; Stephan A Grupp
Journal:  Oncoimmunology       Date:  2015-08-12       Impact factor: 8.110

6.  Modulation of heme oxygenase-1 by metalloporphyrins increases anti-viral T cell responses.

Authors:  C E Bunse; V Fortmeier; S Tischer; E Zilian; C Figueiredo; T Witte; R Blasczyk; S Immenschuh; B Eiz-Vesper
Journal:  Clin Exp Immunol       Date:  2015-02       Impact factor: 4.330

7.  Linear fidelity in quantification of anti-viral CD8+ T cells.

Authors:  Inge E A Flesch; Natasha A Hollett; Yik Chun Wong; David C Tscharke
Journal:  PLoS One       Date:  2012-06-20       Impact factor: 3.240

8.  Potential limitations of the NSG humanized mouse as a model system to optimize engineered human T cell therapy for cancer.

Authors:  Erik M Alcantar-Orozco; Hannah Gornall; Vania Baldan; Robert E Hawkins; David E Gilham
Journal:  Hum Gene Ther Methods       Date:  2013-08-24       Impact factor: 2.396

9.  Immunization with a recombinant vaccinia virus that encodes nonstructural proteins of the hepatitis C virus suppresses viral protein levels in mouse liver.

Authors:  Satoshi Sekiguchi; Kiminori Kimura; Tomoko Chiyo; Takahiro Ohtsuki; Yoshimi Tobita; Yuko Tokunaga; Fumihiko Yasui; Kyoko Tsukiyama-Kohara; Takaji Wakita; Toshiyuki Tanaka; Masayuki Miyasaka; Kyosuke Mizuno; Yukiko Hayashi; Tsunekazu Hishima; Kouji Matsushima; Michinori Kohara
Journal:  PLoS One       Date:  2012-12-17       Impact factor: 3.240

10.  Transcriptional reprogramming of mature CD4⁺ helper T cells generates distinct MHC class II-restricted cytotoxic T lymphocytes.

Authors:  Daniel Mucida; Mohammad Mushtaq Husain; Sawako Muroi; Femke van Wijk; Ryo Shinnakasu; Yoshinori Naoe; Bernardo Sgarbi Reis; Yujun Huang; Florence Lambolez; Michael Docherty; Antoine Attinger; Jr-Wen Shui; Gisen Kim; Christopher J Lena; Shinya Sakaguchi; Chizuko Miyamoto; Peng Wang; Koji Atarashi; Yunji Park; Toshinori Nakayama; Kenya Honda; Wilfried Ellmeier; Mitchell Kronenberg; Ichiro Taniuchi; Hilde Cheroutre
Journal:  Nat Immunol       Date:  2013-01-20       Impact factor: 25.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.